Company: BIAF
Filing Date: 2025-11-12
Form Type: DEFA14A
Source: 0001493152-25-021675
Chunk: 0

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-12
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary                                                       
 Proxy Statement                                                   |
| ☐ | Confidential,                                                     
 for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive                                                        
 Proxy Statement                                                   |
| ☒ | Definitive                                                        
 Additional Materials                                              |
| ☐ | Soliciting                                                        
 Material Pursuant to §240.14a-12                                  |

<div align='center'>bioAffinity Technologies, Inc.

(Exact Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| ☒ | No                                                                                              
 fee required.                                                                                   |
| ☐ | Fee                                                                                             
 paid previously with preliminary materials.                                                     |
| ☐ | Fee                                                                                             
 computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

<div align='center'>bioAffinity Technologies, Inc.

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

SUPPLEMENT TO PROXY STATEMENT

FOR THE SPECIAL MEETING OF STOCKHOLDERS

TO BE HELD ON DECEMBER 19, 2025</div>

The following information supplements and amends the proxy statement of bioAffinity Technologies, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission on November 7, 2025 (the “Proxy Statement”) and furnished to stockholders of the Company in connection with the solicitation of proxies by the Board of Directors of the Company for the Special Meeting (the “Special Meeting”) of Stockholders of the Company to be held on December 19, 2025 and any adjournment or postponement thereof.

The Company is providing this supplement to the Proxy Statement (this “Supplement”) solely to correct the number of shares of common stock outstanding as of November